Skip to main content
AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
253.35
+10.21 (4.20%)
At close: Jun 26, 2026, 4:00 PM EDT
252.98
-0.37 (-0.15%)
After-hours: Jun 26, 2026, 7:59 PM EDT

AbbVie Revenue by Segment
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Immunology
31.43B 30.41B 29.07B 28.24B 27.58B 26.68B 26.34B 26.08B
Immunology Growth
13.99% 13.96% 10.38% 8.27% 6.39% 2.09% -2.83% -6.78%
Neuroscience
11.36B 10.77B 10.32B 9.84B 9.32B 9.00B 8.58B 8.26B
Neuroscience Growth
21.94% 19.65% 20.17% 19.03% 16.64% 16.61% 17.06% 18.70%
Hematologic Oncology
6.65B 6.66B 6.68B 6.69B 6.65B 6.56B 6.37B 6.20B
Hematologic Oncology Growth
0.12% 1.53% 4.85% 7.89% 9.98% 10.82% 5.57% 0.37%
Aesthetics
4.94B 4.86B 4.87B 4.92B 5.03B 5.18B 5.25B 5.25B
Aesthetics Growth
-1.69% -6.11% -7.18% -6.31% -4.08% -2.23% 0.75% -0.44%
Other Products
3.92B 3.74B 3.76B 3.63B 3.56B 3.65B 3.70B 3.79B
Other Products Growth
10.26% 2.41% 1.62% -4.24% -5.85% -4.15% -3.14% -1.51%
Eye Care
1.60B 2.11B 2.18B 2.19B 2.21B 2.24B 2.18B 2.26B
Eye Care Growth
-27.47% -5.93% -0.28% -3.10% -5.76% -7.16% -9.88% -7.26%

Revenue by Geography
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
United States
47.59B 46.60B 45.54B 44.62B 43.97B 43.03B 42.41B 42.11B
United States Growth
8.25% 8.31% 7.40% 5.97% 5.38% 2.74% -1.30% -4.03%
International
15.23B 14.56B 14.10B 13.71B 13.40B 13.31B 13.13B 12.89B
International Growth
13.63% 9.41% 7.41% 6.31% 5.68% 7.00% 7.85% 6.12%

Operating Expense Breakdown
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018
Selling, General, and Administrative
14.30B 14.01B 13.97B 14.61B 14.73B 14.75B 14.09B 13.26B - -
Selling, General, and Administrative Growth
-2.95% -5.03% -0.85% 10.18% 12.03% 14.61% 7.59% 1.76% - -
Research and Development
9.50B 9.10B 13.29B 13.10B 12.92B 12.79B 7.94B 7.54B - -
Research and Development Growth
-26.46% -28.89% 67.31% 73.84% 76.44% 66.66% 5.39% 1.45% - -
Acquired In-Process R&D
5.51B 5.02B 5.33B 2.73B 2.84B 2.76B 1.47B 1.45B - -
Acquired In-Process R&D Growth
94.02% 81.94% 263.48% 88.20% 258.71% 254.37% 98.24% 103.23% - -
Other Expenses
-434.00M -434.00M -48.00M -48.00M
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.